Table 1.
Study Population (n=71)
| Characteristic | Result |
|---|---|
| Age | 53.7±14.5 |
| Height, m | 1.7±0.10 |
| Weight, kg | 84.3±18.7 |
| Sex | |
| Male | 23 (32.4) |
| Female | 48 (67.6) |
| Race | |
| Black | 13 (18.3) |
| White | 58 (81.7) |
| Coronary artery disease | 3 (4.2) |
| Hypertension | 36 (50.7) |
| Diabetes mellitus | 12 (16.9) |
| Hyperlipidemia | 8 (11.4) |
| Smoker at any time | 8 (11.6) |
| Body mass index ≥30 | 30 (42.3) |
| Cancer | |
| Breast | 29 (40.8) |
| Lymphoma | 37 (52.1) |
| Sarcoma | 5 (7.0) |
| Chemotherapy before study | 13 (18.3) |
| Chemotherapy treatment regimen | |
| Anthracycline | 48 (67.6) |
| Trastuzumab | 2 (2.8) |
| Taxane | 28 (39.4) |
| Cyclophosphamide | 49 (69.0) |
| Other chemotherapy | 45 (63.4) |
| Immunotherapy | 23 (32.4) |
| Cardioprotective medication | 39 (54.9) |
Values are n (%) or mean±SE. Cardioprotective medications include use of angiotensin‐converting enzyme inhibitors (22.5%), β‐blockers (18.3%), diuretics (26.8%), and statins (28.2%) at any point during the study.